CERo Therapeutics Holdings (CERo Therapeutics Holdings) Change In Payables And Accrued Expense : $-0.76 Mil (TTM As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Change In Payables And Accrued Expense?

CERo Therapeutics Holdings's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2022 was $-0.76 Mil. It means CERo Therapeutics Holdings's Accounts Payable & Accrued Expense declined by $0.76 Mil from Dec. 2021 to Dec. 2022 .

CERo Therapeutics Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was $-0.76 Mil. It means CERo Therapeutics Holdings's Accounts Payable & Accrued Expense declined by $0.76 Mil from Dec. 2021 to Dec. 2022 .

CERo Therapeutics Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for CERo Therapeutics Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Change In Payables And Accrued Expense Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Change In Payables And Accrued Expense

0.69

-0.76

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Change In Payables And Accrued Expense	0.69	-0.76

CERo Therapeutics Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.76 Mil.

CERo Therapeutics Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024